AUSTRALIAN Prostate Cancer Research (APCR) ceo Mark Harrison (pictured) has been awarded one of two first prizes for his company's development of Prostmate, during a red-carpet announcement at the European Society of Medical Oncology (ESMO) Annual Congress in Copenhagen, Denmark.
"Prostmate is a companion tool designed to support our vision that 'no man dies of prostate cancer'," Harrison explained.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 16